Arcus Biosciences (RCUS) Soars 8.5%: Is Further Upside Left in the Stock?

Core Viewpoint - Arcus Biosciences, Inc. (RCUS) shares experienced an 8.5% increase, closing at $14.48, attributed to higher trading volume and growing investor confidence in the company's pipeline candidates targeting various cancer indications [1][2]. Company Summary - The upcoming quarterly report for Arcus Biosciences is expected to show a loss of $1.28 per share, reflecting a year-over-year decline of 28%. Revenue is projected to be $20.44 million, down 57.4% from the same quarter last year [2]. - The consensus EPS estimate for Arcus has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4]. Industry Summary - Arcus Biosciences operates within the Zacks Medical - Biomedical and Genetics industry, which includes other companies like Ascendis Pharma A/S (ASND). ASND shares increased by 3.3% to $210.83, while its performance over the past month showed a slight decline of 0.9% [5]. - Ascendis Pharma's consensus EPS estimate for its upcoming report is -$0.54, representing a 71.4% improvement from the previous year, and it also holds a Zacks Rank of 3 (Hold) [6].